Why the frenzy to buy Anduril shares is like buying Taylor Swift tickets

The buzz around Anduril has reached a fever pitch, with investors lining up to acquire shares of the defense tech startup even before its next funding round is finalized. Prominent venture capital firms such as Thrive Capital and Andreessen Horowitz are reportedly backing the company at an impressive valuation of $60 billion, prompting others who missed out to scramble for shares on secondary markets, often at inflated prices. Kelly Rodriques, CEO of Forge Global, a marketplace for private company shares, noted the intense demand, stating, "Buyers experiencing fear of missing out (FOMO) are willing to pay substantial premiums for access." Despite the company's disapproval of this situation, the phenomenon continues to unfold. The race to invest in Anduril underscores a growing trend in private markets, where access to the most sought-after startups is often limited to venture capital firms, leaving other investors to pay a premium on the sidelines. Rodriques also mentioned that Anthropic has experienced a similar, though less intense, demand for secondary shares among investors shut out of its fundraising. The current scenario is reminiscent of the frenzy seen when purchasing tickets for a Taylor Swift concert, where fans are willing to pay exorbitant prices on resale platforms like Stubhub. Rodriques described this trend as akin to scalping, highlighting the drastic premiums—up to 40% above the company’s valuation—investors are willing to pay for Anduril shares. However, these transactions are not finalized without agreement from both sellers and the company itself. Greg Martin, managing director at Rainmaker Securities, commented on the unusual size of these premiums, stating, "Typically, we observe premiums in the 5% to 15% range, making the current situation quite remarkable." Anduril’s co-founders, Palmer Luckey and Matt Grimm, have expressed strong opposition to unauthorized share sales, labeling involved firms as "frauds". Grimm cautioned potential investors about the secondary market's risks, remarking, "Secondary markets are rife with fraud and bad actors, and it pains me to see these bottom feeders profiting off Anduril's growth while fleecing retail investors through unreasonable or opaque fee structures." The founders have maintained strict control over Anduril's stock, requiring sellers to offer the company a first right of refusal on any shares or to assign the sale to a buyer of Anduril's choice. This control contributes to the scarcity of shares, which has intensified investor demand. Recent data from Caplight reveals a striking imbalance in the secondary market for Anduril stock, with demand soaring to 97% of total volume while willing sellers only account for 3%—a significant shift from a previous ratio of 69-to-31 in February. Given the soaring interest in Anduril shares, one might wonder why the company doesn't simply raise its share price to capitalize on the demand. Rodriques likened this situation to the pricing strategy of a popular sneaker brand, explaining, "Just because some people are willing to pay more does not mean the company wants to set its prices so high. It’s not in their best interest to charge their customers $2000 for a pair of shoes." Ultimately, Anduril seems more inclined to secure capital from its preferred venture capital investors rather than inflating share prices indiscriminately, having achieved its remarkable $60 billion valuation through careful partnerships with top-tier investors.